IMARC Group, a leading market research company, has recently released a report titled "Cell and Gene Therapy Market by Therapy Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, and Others), Delivery Mode (In-Vivo, Ex-Vivo), End User (Hospitals, Cancer Care Centers, Pharmaceutical & Biotechnology Companies, and Others), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global cell and gene therapy market size, share, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Cell and Gene Therapy Market Highlights:

• Cell and Gene Therapy Market Forecast: The global cell and gene therapy market size is projected to exhibit a growth rate (CAGR) of 14.88% during 2025-2033.
• Market Growth: The cell and gene therapy market is experiencing rapid growth, driven by advancements in biotechnology.
• Investment Surge: Increased investment from both public and private sectors is fueling innovation and development.
• Regulatory Approvals: A growing number of therapies are receiving regulatory approvals, enhancing market confidence.
• Therapeutic Applications: Applications in oncology, rare diseases, and genetic disorders are expanding the market scope.
• Technological Advances: Innovations in CRISPR, viral vectors, and other gene-editing technologies are pivotal.
• Global Reach: The market is witnessing geographical expansion, with significant growth in North America and Europe.
• Challenges: High costs, complex manufacturing processes, and regulatory hurdles remain key challenges.
• Future Outlook: The market is expected to continue its upward trajectory, with ongoing research and development efforts.

Claim Your Free “Cell and Gene Therapy Market” Insights Sample PDF: https://www.imarcgroup.com/cell-gene-therapy-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Industry Trends and Drivers:

• Growing Prevalence of Genetic Disorders and Cancer:

Genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy are becoming more common which will probably help the cell and gene therapy market expand. Therapies target genetic diseases, offering a chance to stabilize or reverse disease at the source and appealing as an option in genetic disorder treatment. The growing number of gene therapies against cancers drives market growth. The medical product modulates immune cells for delivering DNA/RNA to a patient's cells to combat the disease. The increasing trend exists toward personalized medicine, which increases the need for targeted therapies for addressing the unique requirements of individual patients.

• Rapid Technological Advancements in Gene Editing and Delivery:

Market growth may rise because of increased demand in clustered regularly interspaced short palindromic repeats- Cas9 (CRISPR- Cas9), transcription activator-like effector nucleases (TALEN), and zinc-finger nucleases, the precise gene-editing tools. These technologies can edit a specific gene precisely toward curing severe and previously unmanageable genetic disorders. Furthermore, viral and non-viral vector technologies increasingly develop to improve the safety and efficacy of gene delivery to target cells so they should drive the market to grow. Furthermore, the use of new technologies to accurately deliver genetic material and incorporate it into the genome at specific sites minimizes the risk of adverse events and increases the potential for long-term therapeutic benefits. This is expected to expand the cell and gene therapy market size.

• Increasing Regulatory Support and Expedited Approval Processes:

The increase in the support extended by the regulatory agencies for the development and commercialization of cell and gene therapies is also anticipated to increase the market growth. In addition, the increase in the number of special pathways extended by the regulatory agency for the approval of novel therapies is driving the market. Support programs such as the regenerative medicine advanced therapy (RMAT) designation, which allows for faster development and review pathways for treatment of serious or life-threatening conditions, will continue to have a positive impact on the market. Previous experience within the cell and gene space shows that these expedited pathways reduce the time and cost associated with getting new therapies to patients, while also encouraging investment and continued innovation.

Cell and Gene Therapy Market Report Segmentation:

Breakup by Therapy Type:

• Cell Therapy
• Stem Cell
• Pluripotent Stem Cell
• Cancer Stem Cell
• Adult Stem Cell
• Non-Stem Cell
• T Cells
• Natural Killer
• Others
• Gene Therapy

Breakup by Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Breakup by Delivery Mode:

• In-Vivo
• Ex-Vivo

Breakup End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical & Biotechnology Companies
• Others

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

• Amgen Inc.
• Biogen
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Gilead Science
• Kolon TissueGene Inc.
• Orchard Therapeutics plc.
• Pfizer Inc.
• Renova Therapeutics
• Spark Therapeutics, Inc.

Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=6964&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302